KALA BIO has transitioned into a high-risk, pre-revenue clinical-stage entity, with its future entirely contingent on the success of the KPI-012 MSC-S platform. The company's financial profile is characterized by a massive $696.5 million accumulated deficit an...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | -$21.32-255.3% vs -$6.00 | — vs — |
Q2 2026 May 15, 2026 | -$0.14+98.4% vs -$8.50 | — vs — |
Q2 2026 Apr 15, 2026 | $0.08+100.5% vs -$16.00 | — vs — |
Q4 2025 Nov 19, 2025 | -$1.07+97.9% vs -$50.50 | — vs — |
Shares of KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) have received a consensus rating of "Reduce" from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications.
Benchmark KALA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for KALA BIO, Inc. (KALA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.56 | $10.83M | -0.17 | — | — | -279.18% | — | |
| $10.00 | $2.19B | -7.04 | -18.67% | -579.1% | -59.87% | — | |
| $99.97 | $6.51B | 29.32 | 0.5% | 17.69% | 23.27% | — | |
| $33.60 | $1.25B | -240.00 | 36.41% | -13.51% | -104.9% | — | |
| $8.50 | $462.48M | -11.49 | -3.13% | -35.69% | -50.64% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — |
KALA BIO, Inc. (KALA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
KALA BIO, Inc. (KALA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 23, 2026·SEC
May 7, 2026·SEC
Mar 4, 2026·SEC
Get notified when KALA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KALA BIO, Inc. (KALA) stock FAQ — growth, dividends, profitability & financials explained
KALA BIO, Inc. (KALA) reported a net loss of $8.5M for fiscal year 2025.
KALA BIO, Inc. (KALA) has a return on equity (ROE) of -279.2%. Negative ROE indicates the company is unprofitable.
KALA BIO, Inc. (KALA) had negative free cash flow of $19.9M in fiscal year 2025, likely due to heavy capital investments.
